Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer

This study has been terminated.
(Study early termination was due to slow recruitment and difficulties at achieving the required enrolment for the study.)
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00455572
First received: April 2, 2007
Last updated: August 7, 2014
Last verified: August 2014

April 2, 2007
August 7, 2014
May 2007
August 2013   (final data collection date for primary outcome measure)
  • The anti-MAGE-A3 seroconversion [ Time Frame: After the fourth dose of ASCI and at the end of treatment ] [ Designated as safety issue: No ]
  • The anti-protein D seroconversion [ Time Frame: After the fourth dose of ASCI and at the end of treatment ] [ Designated as safety issue: No ]
  • The anti-CpG seroconversion [ Time Frame: After the fourth dose of ASCI and at the end of treatment ] [ Designated as safety issue: No ]
  • The MAGE-A3 cellular (T cell) response [ Time Frame: After the fourth dose of ASCI and at the end of treatment ] [ Designated as safety issue: No ]
  • Occurrence of adverse events, including abnormal hematological and biochemical laboratory values [ Time Frame: During the study ] [ Designated as safety issue: No ]
  • Occurrence of serious adverse events [ Time Frame: During the study ] [ Designated as safety issue: No ]
  • The anti-tumor-antigen humoral response
  • The anti-protein D humoral response
  • The anti-tumor-antigen cellular (T-cell) response
  • Adverse events
  • Serious adverse events
Complete list of historical versions of study NCT00455572 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer
Cancer Immunotherapeutic GSK1572932A as Adjuvant Therapy for Patients With MAGE-A3-positive Non-Small Cell Lung Cancer

The purpose of this clinical trial is to find out how successfully non-small-cell lung cancer patients are able to give an immune response to injections of the immunotherapeutic product GSK1572932A, and to find out more about the safety of this treatment. A course of eight injections will be administered over 21 weeks; including screening for suitability and all tests, the duration of the study for a patient will be 30-35 weeks. During this period various tests will be performed, including physical examinations and blood tests. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

This is an open, four-arm, parallel-group study, to be conducted at approximately 20 centers in Europe and Canada. All patients will receive the same immunotherapeutic treatment with GSK1572932A, but they will be recruited into four cohorts according to the details of their disease. Cohort 1: Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will receive chemo-and immunotherapy in parallel. Cohort 2: Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will first receive chemotherapy and then immunotherapy.

Cohort 3: Patients with resected stage IB, II or IIIA tumors who are not due for chemotherapy. These patients will receive immunotherapy only. Cohort 4: Patients with unresectable stage III tumors, following standard chemotherapy and/or radiotherapy. These patients will receive immunotherapy only. Immunotherapeutic treatment will comprise eight doses of GSK1572932A. Doses will be administered at three-week intervals; in Cohort 1 this may be adapted to fit in with the patient's chemotherapy. During the study, adjuvant radiotherapy is allowed in Cohorts 1, 2 and 3 for patients in stage III only and is prohibited in Cohort 4. Chemotherapy during the study is allowed in Cohort 1 only as described above, and is prohibited in Cohorts 2-4. The total maximum duration of the study for a patient will be 30-35 weeks.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Lung Cancer, Non-Small Cell
  • Biological: Immunotherapeutic GSK1572932A
    Intramuscular injection, 8 doses
  • Drug: Cisplatin (CDDP)
    Four cycles with doses based on patient's body surface area, intravenous administration
  • Drug: Vinorelbine
    Four cycles with doses based on patient's body surface area , intravenous administration
  • Procedure: Radiotherapy
    Regimen will be based upon the site's own standard procedures
  • Experimental: Cohort 1
    Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will receive chemo-and immunotherapy in parallel.
    Interventions:
    • Biological: Immunotherapeutic GSK1572932A
    • Drug: Cisplatin (CDDP)
    • Drug: Vinorelbine
  • Experimental: Cohort 2
    Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will first receive chemotherapy and then immunotherapy
    Interventions:
    • Biological: Immunotherapeutic GSK1572932A
    • Drug: Cisplatin (CDDP)
    • Drug: Vinorelbine
  • Experimental: Cohort 3
    Patients with resected stage IB, II or IIIA tumors who are not due for chemotherapy. These patients will receive immunotherapy only.
    Intervention: Biological: Immunotherapeutic GSK1572932A
  • Experimental: Cohort 4
    Patients with unresectable stage III tumors, following standard chemotherapy and/or radiotherapy. These patients will receive immunotherapy only.
    Interventions:
    • Biological: Immunotherapeutic GSK1572932A
    • Drug: Cisplatin (CDDP)
    • Drug: Vinorelbine
    • Procedure: Radiotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
71
August 2013
August 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Written informed consent obtained,
  • Aged 18 or more,
  • Pathologically proven stage IB, II or III NSCLC,
  • Tumor expresses MAGE-A3,
  • Free of distant metastasis,
  • For Cohort 1, all of the following:

    1. Completely resected stage IB, II or IIIA NSCLC,
    2. Anatomical tumor resection, involving at least a lobectomy, and nodal sampling as per center standard
    3. ECOG performance status = 0 or 1
    4. Due to receive adjuvant chemotherapy as permitted in the protocol
    5. Not received, not receiving, and not due to receive adjuvant radiotherapy (except stage III patients)
    6. First administration of chemotherapy can be scheduled within 4-12 weeks after surgery
  • For Cohort 2, all of the following:

    1. Resected stage IB, II or IIIA NSCLC,
    2. Anatomical tumor resection, involving at least a lobectomy, and nodal sampling as per center standard
    3. ECOG PS = 0 or 1
    4. Due to receive, or receiving, adjuvant chemotherapy as permitted in the protocol
    5. Not received, not receiving, and not due to receive, adjuvant radiotherapy (except stage III patients)
    6. First administration of ASCI treatment can be scheduled within 2-4 weeks after the last administration of chemotherapy
    7. Received at least 2 cycles of standard chemotherapy before ASCI treatment is initiated, whereafter no further chemotherapy is planned
  • For Cohort 3, all of the following:

    1. Resected stage IB, II or IIIA NSCLC
    2. Anatomical tumor resection, involving at least a lobectomy, and nodal sampling as per center standard
    3. ECOG PS = 0 or 1 or 2
    4. Not received, not receiving, and not due to receive, adjuvant chemotherapy
    5. Not received, not receiving, and not due to receive, adjuvant radiotherapy (this does not apply to patients in stage III)
    6. First administration of ASCI treatment can be scheduled within 4-8 weeks after surgery
  • For Cohort 4, all of the following:

    1. Unresectable stage III NSCLC
    2. ECOG PS = 0 or 1 or 2
    3. Due to receive, or receiving, chemo- and radiotherapy according to institution standard
    4. Received at least 2 cycles of standard chemotherapy before the initiation of ASCI treatment, whereafter no further chemo-/radiotherapy is planned
    5. Stable disease or objective response (confirmed by CT scan) after standard chemo-/radiotherapy
    6. Administration of ASCI treatment can be scheduled within 2-6 weeks after the last administration of chemo-/radiotherapy
  • Laboratory criteria: adequate bone-marrow reserve, adequate renal function, adequate hepatic function.
  • For females: EITHER not of child-bearing potential, OR sexually abstinent, OR negative urine pregnancy test + use of adequate contraceptive precautions from 30 days before first study treatment till 2 months after completion of study treatment course
  • In the view of the investigator, the patient can and will comply with the requirements of the protocol

Exclusion criteria:

  • Previous or concomitant other malignancies, except if effectively treated and considered by the investigator highly likely to have been cured
  • Pregnant or lactating
  • History of anaphylaxis or severe allergic reaction
  • Concurrent severe medical problems, unrelated to the malignancy, limiting full compliance with the study or exposing the patient to unacceptable risk
  • Psychiatric or addictive disorders compromising the ability to give informed consent, or to comply with the trial procedures
  • HIV-positive
  • Require treatment with systemic corticosteroids, or other immunosuppressive agents
  • Need home oxygenation
  • Received or plan to receive investigational or non-registered product other than the study medication from 30 days before first dose of study medication and during whole study period
  • History of chronic alcohol consumption and/or drug abuse
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   Canada,   France,   Germany,   Italy,   United Kingdom
 
NCT00455572
107240
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP